The Goldman Sachs Group, Inc.

🇺🇸New York Stock Exchange
Back to all articles
The Goldman Sachs Group, Inc. stock analysis GS overview
Bullish +75

Goldman says stocks like Nvidia have more room to run

📈 Goldman Sachs identifies Nvidia, Samsara, BrightSpring Health Services, Ulta Beauty, and Johnson & Johnson as top picks for the current market.

💰 Analysts project Nvidia will sustain growth through 2027 with estimates over 30% above street consensus.

🏥 BrightSpring Health Services is favored for its differentiated home health care model targeting the aging population.

🚀 Samsara is rated as one of the most defensible growth assets in software with improving profit margins.

💄 Ulta Beauty is expected to gain market share fueled by a healthy cosmetics category and strong execution.

💊 Johnson & Johnson's Innovative Medicine business is viewed as undervalued with $80bn balance sheet capacity.

📉 Goldman advises buying the dip on Ulta Beauty despite a 23% decline this year.

🔒 Samsara's competitive moat is reinforced by customers standardizing physical operations on fewer platforms.

Bullish Signals
  • Goldman Sachs reiterates a Buy rating on Nvidia, projecting sustained growth through 2027 with estimates significantly above street consensus.
  • Samsara is described as one of the most defensible growth assets in software today with solid execution and expanding drivers.
  • BrightSpring Health Services is positioned for premium growth in home health care due to its differentiated service offerings.
  • Ulta Beauty has raised operating income growth and EPS guidance following a solid first-quarter performance.
  • Johnson & Johnson possesses an industry-leading $80 billion balance sheet capacity to support revenue growth in innovative medicines.
  • Analysts believe Ulta's comp acceleration is fueled by a healthy cosmetics category and strong company execution.
  • Samsara's June 24th investor day is viewed as a positive catalyst for the stock.
Full Analysis
Goldman Sachs analysts have identified several stocks as well-positioned for growth in the current market environment, highlighting Nvidia, Samsara, BrightSpring Health Services, Ulta Beauty, and Johnson & Johnson. The bank emphasizes that these companies offer a mix of defensive qualities and significant upside potential, with specific praise for their execution, competitive moats, and strategic positioning within their respective sectors. Regarding Nvidia, Goldman reiterates its Buy rating, citing improved capital allocation and a commitment to balancing innovation with shareholder returns. Analysts project that the company will sustain its growth profile through 2027, with current estimates standing over 30% above street consensus. For Samsara, the bank views it as a defensible growth asset in software, noting solid execution and expanding growth drivers following a recent earnings report. BrightSpring Health Services is highlighted for its differentiated offering in home health care, which positions it best for growth in serving the aging population. Analysts initiated coverage with a Buy rating and a $71 price target, praising the company's ability to navigate fragmentation in pharmacy and provider markets. Ulta Beauty is seen as well-positioned to gain market share despite recent stock weakness, with analysts believing margin concerns are overdone after a solid first-quarter performance. Johnson & Johnson is noted for its strengthening pharma franchise, specifically the Innovative Medicine business, which consensus may be under-appreciating. With an industry-leading $80 billion in balance sheet capacity, J&J is expected to continue augmenting revenue growth in this area. Goldman maintains a Buy rating on the stock, viewing it as a defensive bellwether with strong long-term trajectory.